Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 804-807

  Takii, Takemasa ^a   Hamasaki, Sonomi ^b   Hirano, Kazue ^b   Abe, Chiyoji ^b   Onozaki, Kikuo ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; FIBROBLAST; GENE SEGREGATION; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; FIBROBLASTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBERCULOSIS;

EID: 12944327875     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.804-807.2005     Document Type: Article

References (24)

1. Alcaide, F., and A. Telenti. 1997. Molecular techniques in the diagnosis of drug-resistant tuberculosis. Ann. Acad. Med. Singapore 26:647-650.
2. Aono, A., K. Hirano, S. Hamasaki, and C. Abe. 2002. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn. Microbiol. Infect. Dis. 44:347-352.
3. Bergmann, J. S., and G. L. Woods. 1998. Evaluation of the ESP Culture System II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs. J. Clin. Microbiol. 36:2940-2943.
4. Carlone, N. A., G. Acocella, A. M. Cuffini, and M. Forno-Pizzoglio. 1985. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am. Rev. Respir. Dis. 132: 1274-1277.
5. Centers for Disease Control and Prevention. 1993. Initial therapy for tuberculosis in the era of multidrug resistance, Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb. Mortal. Wkly. Rep. 42(RR-7):1-8.
6. Crowle, A. J., J. A. Sbarbaro, and M. H. May. 1986. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am. Rev. Respir. Dis. 134:1052-1055.
7. Heifets, L., and T. Sanchez. 2000. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 38:1498-1501.
8. Hirano, K., M. Takahashi, Y. Kazumi, Y. Fukazawa, and C. Abe. 1998. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercle Lung Dis. 78:117-122.
9. Konno, K., F. M. Feldmann, and W. McDermott. 1967. Pyrazinamide susceptibility and amidase actvity of tubercle bacilli. Am. Rev. Respir. Dis. 95: 461-469.
10. LaBombardi, V. J. 2002. Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide. J. Clin. Microbiol. 40:2238-2239.
11. Mitchison, D. A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
12. Perez-Stable, E. J., and P. C. Hopewell. 1988. Chemotherapy of tuberculosis. Semin. Respir. Med. 9:459-469.
13. Rastogi, N., V. Labrousse, and K. S. Goh. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33: 167-175.
14. Salfinger, M., A. J. Crowle, and L. B. Reller. 1990. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J. Infect. Dis. 162:201-207.
15. Sbarbaro, J. A., M. D. Iseman, and A. J. Crowle. 1996. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber. Lung. Dis. 77:491-495.
16. Scorpio, A., P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and Y. Zhang. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543.
17. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculosis drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
18. Sreevatsan, S., X. Pan, Y. Zhang, B. N. Kreiswirth, and J. M. Musser. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41: 636-640.
19. Takii, T., C. Abe, A. Tamura, S. Ramayah, J. T. Belisle, P. J. Brennan, and K. Onozaki. 2001. Interleukin 1 or tumor necrosis factor α augmented cytotoxic effect of mycobacteria on human fibroblasts: application to evaluation of pathogenesis of clinical isolates of M. tuberculosis and M. avium complex. J. Interferon Cytokine Res. 21:187-196.
20. Takii, T., Y. Yamamoto, T. Chiba, C. Abe, J. T. Belisle, P. J. Brennan, and K. Onozaki. 2002. Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2533-2539.
21. Tummon, R. 1975. Growth inhibition of Mycobacterium tuberculosis by oleate in acidified medium. Med. Lab. Technol. 32:229-232.
22. Wayne, L. G. 1974. Simple pyrazinamide and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
23. World Health Organization. 2000. Anti-tuberculosis drug resistance in the world. World Health Organization, Geneva, Switzerland. [Online.] http: //www.who.int/gtb/publications/dritw/contents.htm.
24. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze, and W. R. Jacobs, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.